Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,962 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (534)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01817075 | Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant | completed | Phase 3 | 177 | Children's Oncology GroupNETWORK | 3 | Jun 22, 2021 | clinicaltrials |
| NCT01307579 | Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia | completed | Phase 3 | 517 | Children's Oncology GroupNETWORK | 3 |
| Mar 30, 2021 |
| clinicaltrials |
| NCT00606723 | Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML | completed | Phase 3 | 154 | Hannover Medical SchoolOTHER | 3 | Mar 22, 2021 | clinicaltrials |
| NCT02039726 | (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive | completed | Phase 3 | 367 | Daiichi SankyoINDUSTRY | 19 | Feb 24, 2021 | clinicaltrials |
| NCT00469144 | IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome | completed | Phase 3 | 233 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT01371656 | Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation | completed | Phase 3 | 624 | Children's Oncology GroupNETWORK | 2 | Dec 7, 2020 | clinicaltrials |
| NCT00822393 | Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) | completed | Phase 3 | 570 | medac GmbHINDUSTRY | 6 | Jul 30, 2020 | clinicaltrials |
| NCT01854567 | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | completed | Phase 3 | 49 | Mesoblast, Ltd.INDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02319135 | Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia(FLUGAZA) | completed | Phase 3 | 289 | PETHEMA FoundationOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02870777 | MRD-directed Therapy for Low-risk and Intermediate-risk AML. | completed | Phase 2 / Phase 3 | 743 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02671708 | IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT | completed | Phase 2 / Phase 3 | 153 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT00952588 | Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients(SPARK-AML1) | completed | Phase 2 / Phase 3 | 74 | AstraZenecaINDUSTRY | 9 | Feb 24, 2020 | clinicaltrials |
| NCT00887068 | Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129) | completed | Phase 3 | 187 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT00260832 | Trial of Decitabine in Patients With Acute Myeloid Leukemia | completed | Phase 3 | 485 | Eisai Inc.INDUSTRY | 15 | Sep 11, 2019 | clinicaltrials |
| NCT02474290 | Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML | completed | Phase 2 / Phase 3 | 202 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT01295710 | Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) | completed | Phase 3 | 260 | Neovii BiotechINDUSTRY | 2 | Apr 9, 2019 | clinicaltrials |
| NCT01802333 | Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 3 | 754 | National Cancer Institute (NCI)NIH | 2 | Dec 19, 2018 | clinicaltrials |
| NCT01191801 | Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML(VALOR) | completed | Phase 3 | 711 | Sunesis PharmaceuticalsINDUSTRY | 15 | Aug 22, 2018 | clinicaltrials |
| NCT01237808 | Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation | completed | Phase 3 | 144 | University of UlmOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT00656448 | A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS | completed | Phase 3 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01382147 | Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)(AMLCG 2008) | completed | Phase 3 | 396 | Prof. Dr. Wolfgang HiddemannOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00151242 | Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 / Phase 3 | 920 | University of UlmOTHER | 2 | Sep 20, 2017 | clinicaltrials |
| NCT01074047 | Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) | completed | Phase 3 | 488 | CelgeneINDUSTRY | 18 | Aug 29, 2017 | clinicaltrials |
| NCT00075478 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | completed | Phase 3 | 87 | Fred Hutchinson Cancer CenterOTHER | 3 | May 15, 2017 | clinicaltrials |
| NCT00151255 | All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 500 | University of UlmOTHER | 2 | Apr 19, 2017 | clinicaltrials |
| NCT00860639 | Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk(LAM2006IR) | completed | Phase 3 | 327 | Nantes University HospitalOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT00093990 | Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 3 | 457 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Sep 14, 2016 | clinicaltrials |
| NCT00476541 | NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia | completed | Phase 3 | 250 | University of AarhusOTHER | 1 | May 13, 2016 | clinicaltrials |
| NCT00495287 | A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML) | completed | Phase 3 | 573 | Northern Italy Leukemia GroupOTHER | 1 | Mar 31, 2016 | clinicaltrials |
| NCT00469729 | Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy(ExCell) | completed | Phase 2 / Phase 3 | 101 | Gamida Cell -Teva Joint Venture Ltd.OTHER | 5 | Jul 10, 2015 | clinicaltrials |
| NCT02461121 | HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk | completed | Phase 3 | 156 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00678275 | Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia | completed | Phase 3 | 161 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00322101 | Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia | completed | Phase 3 | 25 | Fred Hutchinson Cancer CenterOTHER | 2 | Oct 31, 2014 | clinicaltrials |
| NCT00909168 | Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)(MYFLAI07) | completed | Phase 2 / Phase 3 | 130 | University Hospital, Udine, ItalyOTHER | 1 | May 6, 2014 | clinicaltrials |
| NCT00317642 | A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I) | completed | Phase 3 | 326 | Genzyme, a Sanofi CompanyINDUSTRY | 5 | Apr 14, 2014 | clinicaltrials |
| NCT00590837 | Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old(LAM-SA 2007) | completed | Phase 3 | 459 | University Hospital, BordeauxOTHER | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00428558 | Timed-Sequential Induction in CBF-AML | completed | Phase 3 | 200 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 20, 2013 | clinicaltrials |
| NCT01110824 | Prevention of Left Ventricular Dysfunction During Chemotherapy(OVERCOME) | completed | Phase 3 | 90 | Hospital Clinic of BarcelonaOTHER | 1 | Nov 15, 2013 | clinicaltrials |
| NCT01147939 | Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)(CLAVELA) | completed | Phase 3 | 381 | Clavis PharmaINDUSTRY | 13 | Sep 27, 2013 | clinicaltrials |
| NCT00927498 | A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old | completed | Phase 3 | 280 | Acute Leukemia French AssociationOTHER | 1 | Jul 11, 2013 | clinicaltrials |
| NCT00003934 | Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia | completed | Phase 3 | 420 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00003190 | Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 3 | 640 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00006363 | Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia | completed | Phase 3 | 720 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT01188798 | Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies | completed | Phase 3 | 6 | St. Jude Children's Research HospitalOTHER | 1 | Mar 21, 2013 | clinicaltrials |
| NCT00398983 | Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML) | completed | Phase 2 / Phase 3 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 4, 2013 | clinicaltrials |
| NCT00002798 | Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | completed | Phase 3 | 880 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00266136 | Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG) | completed | Phase 3 | 3,500 | University Hospital MuensterOTHER | 1 | Oct 26, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT00474006 | High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML(ADcomparison) | completed | Phase 3 | 398 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
Data updated 23 days agoSource updated Jun 22, 2021source: clinicaltrials